SeekingAlpha · Sep 15, 2026
Rigel Pharmaceuticals, Inc. (RIGL) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference - Slideshow
2026-09-15. The following slide deck was published by Rigel Pharmaceuticals, Inc.
RI
NASDAQ · RIGL
Rigel Pharmaceuticals, Inc.
Healthcare · Biotechnology
$47.79
Down-$1.68 (-3.52%)
Updated Oct 7, 2026, 1:51 AM
SID Score
7.1/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 751.68M
- P/E ratio
- 6.71
- Dividend yield
- 0.00%
- 52-week range
- $24.95 – $52.24
- Volume
- 391.63K
- Avg. volume
- 631.51K
Price performance · RIGL
RIGL price history
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 5, 2026
RIGL closed at $47.79 after 20 trading sessions, up 0.89% for the selected period.
- Last close
- $47.79
- Period change
- +0.89%
- Period low
- $44.36
- Period high
- $49.36
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 5, 2026 | $47.02 | $48.8346 | $46.93 | $47.79 | 391.63K |
| Oct 2, 2026 | $47.66 | $48.00 | $46.45 | $47.15 | 185.67K |
| Oct 1, 2026 | $48.05 | $48.87 | $46.81 | $46.97 | 235K |
| Sep 30, 2026 | $49.27 | $49.70 | $47.8039 | $48.15 | 252.21K |
| Sep 29, 2026 | $49.38 | $49.70 | $48.61 | $48.89 | 182.26K |
| Sep 28, 2026 | $48.16 | $49.645 | $47.49 | $49.36 | 180.88K |
| Sep 25, 2026 | $48.23 | $48.53 | $47.20 | $48.18 | 204.93K |
| Sep 24, 2026 | $47.87 | $48.14 | $47.00 | $47.89 | 143.82K |
| Sep 23, 2026 | $48.62 | $48.69 | $46.9101 | $48.13 | 151.38K |
| Sep 22, 2026 | $47.50 | $49.02 | $47.23 | $48.82 | 242.88K |
| Sep 21, 2026 | $47.13 | $47.505 | $46.4936 | $47.09 | 164.84K |
| Sep 18, 2026 | $45.54 | $46.99 | $45.24 | $46.64 | 939.57K |
| Sep 17, 2026 | $45.25 | $46.27 | $45.14 | $45.85 | 165.75K |
| Sep 16, 2026 | $44.14 | $45.37 | $43.78 | $44.48 | 226.41K |
| Sep 15, 2026 | $45.14 | $46.255 | $44.22 | $44.36 | 269.89K |
| Sep 14, 2026 | $47.32 | $47.53 | $44.96 | $45.35 | 335.81K |
| Sep 11, 2026 | $47.84 | $47.86 | $47.00 | $47.24 | 187.18K |
| Sep 10, 2026 | $46.69 | $47.35 | $46.2838 | $47.28 | 131.33K |
| Sep 9, 2026 | $46.85 | $47.8799 | $46.775 | $47.22 | 177.15K |
| Sep 8, 2026 | $48.09 | $48.11 | $46.61 | $47.37 | 248.4K |
Latest RIGL news
The latest Smart Investors Daily articles mentioning RIGL.
Stock researchCompany · Overview
Company
Market Activity
Research & News
RIGL research
Overview
Company profile and research snapshot.
Company profile
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $40.00
- Implied upside
- —
- Analysts
- 12
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 17, 2026 | Piper Sandler | Neutral | — |
| Aug 14, 2026 | HC Wainwright & Co. | Buy | — |
| Jun 2, 2026 | HC Wainwright & Co. | Buy | — |
| May 27, 2026 | HC Wainwright & Co. | Buy | — |
| May 22, 2026 | HC Wainwright & Co. | Buy | — |
News briefing
No generated briefing is available yet.
SeekingAlpha · Sep 15, 2026
Rigel Pharmaceuticals, Inc. (RIGL) Presents at H.C. Wainwright 28th Annual Global Investment Conference - Slideshow
2026-09-15. The following slide deck was published by Rigel Pharmaceuticals, Inc.
Benzinga · Sep 4, 2026
EVP & Chief Financial Officer At Rigel Pharmaceuticals Exercises Options Worth $123K
A large exercise of company stock options by Dean Schorno, EVP & Chief Financial Officer at Rigel Pharmaceuticals (NASDAQ:RIGL) was disclosed in a new SEC filing on September 3, as part of an insider exercise. What
Yahoo · Sep 2, 2026
Rigel to Participate in Upcoming September Investor Conferences
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that Dean Schorno, the company's chief financial officer, will participate in the following investor conferences in September:
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
